Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Phase 1b/2a Study Combining LY2157299 With Standard Temozolomide-based Radiochemotherapy in Patients With Newly Diagnosed Malignant Glioma

NCT01220271 is registered in ClinicalTrials.gov with Eli Lilly and Company as lead sponsor.

NCT NCT01220271
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT01220271 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Phase 1b/2a Study Combining LY2157299 With Standard Temozolomide-based Radiochemotherapy in Patients With Newly Diagnosed Malignant Glioma
Lead sponsor
Eli Lilly and Company
Phase
Phase 1/2
Overall status
Completed
Start date
April 30, 2011
Completion date
November 30, 2016
Enrollment
75 (actual)
Sites
10

Conditions

As the registry lists them; a condition with its own page is linked.

glioma